3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine
• 英文别名: 3-[(4R)-6,8-dichloro-2-methyl-3,4-dihydro-1H-isoquinolin-4-yl]aniline
• 化学式: C₁₆H₁₆Cl₂N₂
• 分子量: 307.222
• InChiKey: ITSVCLWKVUKMHH-CQSZACIVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine 、 2-甲氧基氯甲酸乙酯 在 盐酸 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 [4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenyl]-carbamic acid 2-methoxy-ethyl ester; hydrochloride
  参考文献：
  名称：

  [DE] SUBSTITUIERTE 4-PHENYLTETRAHYDROISOCHINOLINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT, SOWIE SIE ENTHALTENDES MEDIKAMENT
  [EN] SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS
  [FR] 4-PHENYLTETRAHYDROISOQUINOLEINE SUBSTITUEE, SON PROCEDE DE FABRICATION, SON UTILISATION COMME MEDICAMENT, ET MEDICAMENT CONTENANT CE COMPOSE

  摘要：

  该发明涉及公式I中R1至R9具有索赔中所述含义的连接。含有这种类型连接的药物在预防或治疗各种疾病方面是有用的。因此，这些连接可以用于肾脏疾病（如急性或慢性肾衰竭）、胆功能紊乱、呼吸问题（如打鼾或睡眠呼吸暂停）或中风等情况。

  公开号：

  WO2004085404A1
• 作为产物：
  描述：

  3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine 生成 3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine 、 (S)-3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydro-isoquinolin-4-yl)-phenylamine
  参考文献：
  名称：

  [DE] SUBSTITUIERTE 4-PHENYLTETRAHYDROISOCHINOLINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT, SOWIE SIE ENTHALTENDES MEDIKAMENT
  [EN] SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS
  [FR] 4-PHENYLTETRAHYDROISOQUINOLEINE SUBSTITUEE, SON PROCEDE DE FABRICATION, SON UTILISATION COMME MEDICAMENT, ET MEDICAMENT CONTENANT CE COMPOSE

  摘要：

  该发明涉及公式I中R1至R9具有索赔中所述含义的连接。含有这种类型连接的药物在预防或治疗各种疾病方面是有用的。因此，这些连接可以用于肾脏疾病（如急性或慢性肾衰竭）、胆功能紊乱、呼吸问题（如打鼾或睡眠呼吸暂停）或中风等情况。

  公开号：

  WO2004085404A1

文献信息

• Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
  申请人：Hofmeister Armin

  公开号：US20050009863A1

  公开（公告）日：2005-01-13

  Substituted 4-phenyltetrahydroisoquinolines of formula I, process for their preparation, their use as a medicament and medicaments containing them. The compounds of formula I can be used, among other uses, in the event of renal disorders such as acute or chronic renal failure, in the event of disorders of biliary function, in the event of respiratory disorders such as snoring or sleep apneas or in the event of stroke.

  公式I的4-苯基四氢异喹啉替代物，其制备方法，它们作为药物的用途以及含有它们的药物。公式I的化合物可用于其他用途，例如在肾功能障碍如急性或慢性肾衰竭，胆功能障碍，呼吸障碍如打鼾或睡眠呼吸暂停或中风的情况下使用。
• COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS
  申请人：Ardelyx, Inc.

  公开号：EP3351248A1

  公开（公告）日：2018-07-25

  The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract

  本公开内容涉及用于治疗与体液潴留或盐负荷过重相关的疾病的化合物和方法，如心力衰竭（尤其是充血性心力衰竭）、慢性肾病、终末期肾病、肝病和过氧化物酶体增殖激活受体（PPAR）γ激动剂诱导的体液潴留。本公开还涉及治疗高血压的化合物和方法。本公开还涉及治疗胃肠道疾病的化合物和方法，包括治疗或减轻与胃肠道疾病相关的疼痛。这些方法一般包括向有需要的哺乳动物施用药学上有效量的化合物或包含这种化合物的药物组合物，这种化合物在胃肠道中基本具有活性，可抑制其中钠离子和氢离子的NHE介导的反转运。更具体地说，该方法包括向有需要的哺乳动物施用药学上有效量的化合物或包含该化合物的药物组合物，该化合物可抑制胃肠道中NHE-3、-2和/或-8介导的钠离子和/或氢离子的反转运，且设计成基本上不渗透上皮细胞层，或更具体地说不渗透胃肠道上皮细胞。由于该化合物基本上不渗透，因此不会被吸收，从而基本上不会被全身生物利用，从而限制了其他内脏器官（如肝脏、心脏、大脑等）对该化合物的接触。本公开内容还进一步涉及一种方法，在这种方法中，哺乳动物与吸液聚合物一起服用这种化合物，从而使这种组合起到如上所述的作用，并进一步提供封存存在于消化道中的液体和/或盐的能力。
• SUBSTITUIERTE 4-PHENYLTETRAHYDROISOCHINOLINE, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG ALS MEDIKAMENT, SOWIE SIE ENTHALTENDES MEDIKAMENT
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1613600B1

  公开（公告）日：2015-12-23
• EP1613600A1
  申请人：——

  公开号：EP1613600A1

  公开（公告）日：2006-01-11
• US7241775B2
  申请人：——

  公开号：US7241775B2

  公开（公告）日：2007-07-10